Laura Hunt, MD
Family Medicine · Easley, SCNPI 1780606780
Payments from drug & device makers
Across 319 payments — averaging $12.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$539
- AbbVie$460
- AstraZeneca$323
- Lilly USA, LLC$294
- Astellas Pharma US Inc$237
- GSK$224
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,01198%
- Education$992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 51 | $539 |
| AbbVie(2 entities) | 52 | $460 |
| AstraZeneca | 23 | $323 |
| Lilly USA, LLC | 27 | $294 |
| Astellas Pharma US Inc | 9 | $237 |
| GSK | 16 | $224 |
| Merck | 20 | $181 |
| Boehringer Ingelheim | 12 | $180 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $175 |
| Pfizer | 10 | $152 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $150 |
| Amarin Pharma, Inc. | 10 | $147 |
| Novartis | 9 | $143 |
| Amgen | 9 | $127 |
| Kowa Pharmaceuticals America, Inc. | 4 | $66 |
| Arbor Pharmaceuticals, Inc. | 5 | $65 |
| Esperion Therapeutics, Inc. | 4 | $60 |
| Lundbeck LLC | 3 | $60 |
| Abbott | 3 | $49 |
| Sanofi-aventis U.S. LLC | 4 | $49 |
| Daiichi Sankyo Inc. | 2 | $47 |
| Bayer | 3 | $45 |
| Dexcom, Inc. | 3 | $38 |
| Philips North America LLC | 2 | $38 |
| Exact Sciences | 2 | $31 |
| Axsome Therapeutics, Inc. | 1 | $31 |
| Antares Pharma, Inc. | 2 | $30 |
| Eisai Inc. | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| United Therapeutics Corporation | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Hologic Sales And Service, LLC | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Clarus Therapeutics Inc. | 1 | $13 |
| Biosense Webster, Inc. | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
| Genentech USA, Inc. | 1 | $12 |
How this compares
$4,110 in reported general payments places this provider in the 80th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 114 | $150,808 |
| OzempicSemaglutide | 106 | $124,488 |
| JardianceEmpagliflozin | 97 | $108,887 |
| IngrezzaValbenazine Tosylate | 11 | $93,654 |
| Dupixent PenDupilumab | 12 | $46,779 |
| XifaxanRifaximin | 13 | $39,502 |
| EliquisApixaban | 35 | $37,982 |
| FarxigaDapagliflozin Propanediol | 42 | $37,286 |
| JanuviaSitagliptin Phosphate | 39 | $33,606 |
| MyrbetriqMirabegron | 40 | $24,608 |
| XareltoRivaroxaban | 26 | $23,016 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $21,028 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $20,115 |
| UbrelvyUbrogepant | 13 | $20,065 |
| Tresiba Flextouch U-100Insulin Degludec | 33 | $19,329 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $294 | $150,808114 claims |
| Novo NordiskOzempic | $539 | $124,488106 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $180 | $114,288109 claims |
| AbbVieUbrelvy, Vraylar, Linzess | $460 | $46,73740 claims |
| AstraZenecaFarxiga, Symbicort | $323 | $40,57154 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $150 | $39,50213 claims |
| PfizerEliquis | $152 | $37,98235 claims |
| MerckJanuvia | $181 | $33,60639 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $224 | $32,53136 claims |
| Astellas Pharma US IncMyrbetriq | $237 | $24,60840 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Easley
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
- Edward NewtonCharleston$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.